Prescient Therapeutics Ltd

ASX:PTX ISIN:AU000000PTX3

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. 
 
           

Lihat di Bahasa Lain

Berita

Laporan Pasar Australia 14 Februari 2011: Black Fire Minerals (ASX:BFE) Akan Mengakuisisi Proyek Tungsten/Tembaga di AS

🕔2/14/2011 12:20:00 PM 28778

Laporan Pasar Australia 14 Februari 2011 memuat: Black Fire Minerals Limited (ASX:BFE) tengah mengakuisisi 100% kepemilikan lanjutan Proyek Tungsten-Tembaga Pilot Mountain di Nevada, Amerika Serikat; Virax Holdings Limited (ASX:VHL) sedang membangun produk untuk pengobatan kanker kulit yang unggu; Southern Cross Goldfields Limited (ASX:SXG) menemukan cadangan emas bermutu tinggi di dekat permukaan di Australia Barat; Prosperity Resources Limited (ASX:PSP) memulai penggalian emas di Indonesia.

Baca Full Story
###

134,699 TAMPILAN PROFIL PERUSAHAAN

  • Halaman ini dilihat: (7 Hari Terakhir: 12) (30 Hari Terakhir: 61) (Sejak Ditampilkan: 10539) 

Data Perusahaan

    Fax
  • (03) 9853 5134 
  • Sektor Utama
  • Kesehatan & Pharm 
  • Industri Utama
  • Biotechnology 
  • Homepage
  • www.virax.com.au/

Lebih banyak Berita lagi

  • 2024/12/17: Appointment of Chief Executive Officer*
  • 2024/12/11: Change of Director's Interest Notice*
  • 2024/12/11: Notification regarding unquoted securities - PTX*
  • 2024/12/04: Change of Director's Interest Notices x4*
  • 2024/12/04: Notification of cessation of securities - PTX*
  • 2024/11/14: Results of Annual General Meeting*
  • 2024/11/14: Chair and CEO AGM Presentation*
  • 2024/10/31: September 2024 Quarterly Update and Appendix 4C*
  • 2024/10/14: Notice of Annual General Meeting/Proxy Form*
  • 2024/10/03: Change of Director's Interest Notice*
*refer to company website